Bone morphogenetic protein 7 promotes resistance to immunotherapy.
Animals
Antibodies, Monoclonal, Humanized
/ pharmacology
Bone Morphogenetic Protein 7
/ genetics
CD4-Positive T-Lymphocytes
Cell Line, Tumor
Drug Resistance, Neoplasm
/ drug effects
Female
Follistatin
/ metabolism
Gene Expression Regulation, Neoplastic
Gene Knockdown Techniques
Humans
Immunotherapy
/ methods
Mice
Mitogen-Activated Protein Kinase 14
/ genetics
Neoplasms
/ metabolism
Programmed Cell Death 1 Receptor
/ drug effects
RAW 264.7 Cells
Smad1 Protein
/ metabolism
Transcriptome
Tumor Microenvironment
/ drug effects
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
24 09 2020
24 09 2020
Historique:
received:
03
07
2019
accepted:
26
08
2020
entrez:
25
9
2020
pubmed:
26
9
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Immunotherapies revolutionized cancer treatment by harnessing the immune system to target cancer cells. However, most patients are resistant to immunotherapies and the mechanisms underlying this resistant is still poorly understood. Here, we report that overexpression of BMP7, a member of the TGFB superfamily, represents a mechanism for resistance to anti-PD1 therapy in preclinical models and in patients with disease progression while on immunotherapies. BMP7 secreted by tumor cells acts on macrophages and CD4
Identifiants
pubmed: 32973129
doi: 10.1038/s41467-020-18617-z
pii: 10.1038/s41467-020-18617-z
pmc: PMC7519103
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
BMP7 protein, human
0
Bone Morphogenetic Protein 7
0
Follistatin
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
SMAD1 protein, human
0
Smad1 Protein
0
atezolizumab
52CMI0WC3Y
Mitogen-Activated Protein Kinase 14
EC 2.7.11.24
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4840Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
pubmed: 3544539
pmcid: 3544539
doi: 10.1056/NEJMoa1200690
Gettinger, S. & Herbst, R. S. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. Cancer J. 20, 281–289 (2014).
doi: 10.1097/PPO.0000000000000063
pubmed: 25098289
Kelderman, S., Schumacher, T. N. & Haanen, J. B. Acquired and intrinsic resistance in cancer immunotherapy. Mol. Oncol. 8, 1132–1139 (2014).
pubmed: 25106088
pmcid: 5528612
doi: 10.1016/j.molonc.2014.07.011
Wang, X. et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res. 77, 839–850 (2017).
doi: 10.1158/0008-5472.CAN-15-3142
pubmed: 27821490
Kretzschmar, M., Liu, F., Hata, A., Doody, J. & Massague, J. The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev. 11, 984–995 (1997).
doi: 10.1101/gad.11.8.984
pubmed: 9136927
Liu, F. et al. A human Mad protein acting as a BMP-regulated transcriptional activator. Nature 381, 620–623 (1996).
doi: 10.1038/381620a0
pubmed: 8637600
Kretzschmar, M., Doody, J. & Massague, J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 389, 618–622 (1997).
doi: 10.1038/39348
pubmed: 9335504
Aoki, M. et al. Expression of BMP-7 in human gastric cancer and its clinical significance. Br. J. cancer 104, 714–718 (2011).
pubmed: 21224856
pmcid: 3049585
doi: 10.1038/sj.bjc.6606075
Motoyama, K. et al. Clinical significance of BMP7 in human colorectal cancer. Ann. Surg. Oncol. 15, 1530–1537 (2008).
doi: 10.1245/s10434-007-9746-4
pubmed: 18259822
Megumi, K. et al. Clinicopathological significance of BMP7 expression in esophageal squamous cell carcinoma. Ann. Surg. Oncol. 19, 2066–2071 (2012).
doi: 10.1245/s10434-011-2024-5
pubmed: 21913019
Alarmo, E. L., Kuukasjarvi, T., Karhu, R. & Kallioniemi, A. A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast cancer Res. Treat. 103, 239–246 (2007).
doi: 10.1007/s10549-006-9362-1
pubmed: 17004110
Alarmo, E. L. et al. Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. Genes Chromosomes Cancer 45, 411–419 (2006).
doi: 10.1002/gcc.20307
pubmed: 16419056
Rothhammer, T. et al. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res. 65, 448–456 (2005).
pubmed: 15695386
Chen, J. et al. Expression of bone morphogenetic protein 7 in lung cancer and its biological impact on lung cancer cells. Anticancer Res. 30, 1113–1120 (2010).
pubmed: 20530416
Liu, Y., Chen, J., Yang, Y., Zhang, L. & Jiang, W. G. Muolecular impact of bone morphogenetic protein 7, on lung cancer cells and its clinical significance. Int. J. Mol. Med. 29, 1016–1024 (2012).
doi: 10.3892/ijmm.2011.872
pubmed: 22447022
Chen, W. & Ten Dijke, P. Immunoregulation by members of the TGFbeta superfamily. Nat. Rev. Immunol. 16, 723–740 (2016).
doi: 10.1038/nri.2016.112
pubmed: 27885276
Hong, J. H. et al. Effect of bone morphogenetic protein-6 on macrophages. Immunology 128, e442–e450 (2009).
pubmed: 19191909
pmcid: 2753950
doi: 10.1111/j.1365-2567.2008.02998.x
Lee, J. H. et al. BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages. Cancer Res. 73, 3604–3614 (2013).
doi: 10.1158/0008-5472.CAN-12-4563
pubmed: 23633487
Martinez, V. G. et al. The canonical BMP signaling pathway is involved in human monocyte-derived dendritic cell maturation. Immunol. Cell Biol. 89, 610–618 (2011).
doi: 10.1038/icb.2010.135
pubmed: 21102536
Rocher, C., Singla, R., Singal, P. K., Parthasarathy, S. & Singla, D. K. Bone morphogenetic protein 7 polarizes THP-1 cells into M2 macrophages. Can. J. Physiol. Pharmacol. 90, 947–951 (2012).
doi: 10.1139/y2012-102
pubmed: 22720873
Singla, D. K., Singla, R. & Wang, J. BMP-7 treatment increases M2 macrophage differentiation and reduces inflammation and plaque formation in Apo E-/- mice. PloS ONE 11, e0147897 (2016).
pubmed: 26824441
pmcid: 4732822
doi: 10.1371/journal.pone.0147897
Rocher, C. & Singla, D. K. SMAD-PI3K-Akt-mTOR pathway mediates BMP-7 polarization of monocytes into M2 macrophages. PloS ONE 8, e84009 (2013).
pubmed: 24376781
pmcid: 3869858
doi: 10.1371/journal.pone.0084009
Li, R. X. et al. BMP7 reduces inflammation and oxidative stress in diabetic tubulopathy. Clin. Sci. (Lond.) 128, 269–280 (2015).
doi: 10.1042/CS20140401
Takahashi, M. et al. Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation. J. Endocrinol. 199, 445–455 (2008).
doi: 10.1677/JOE-08-0226
pubmed: 18780779
Hu, M. C., Wasserman, D., Hartwig, S. & Rosenblum, N. D. p38MAPK acts in the BMP7-dependent stimulatory pathway during epithelial cell morphogenesis and is regulated by Smad1. J. Biol. Chem. 279, 12051–12059 (2004).
doi: 10.1074/jbc.M310526200
pubmed: 14718543
Klatte-Schulz, F. et al. An investigation of BMP-7 mediated alterations to BMP signalling components in human tenocyte-like cells. Sci. Rep. 6, 29703 (2016).
pubmed: 27406972
pmcid: 4942578
doi: 10.1038/srep29703
Chang, H. M. et al. Recombinant BMP4 and BMP7 downregulate pentraxin 3 in human granulosa cells. J. Clin. Endocrinol. Metab. 100, E365–E374 (2015).
doi: 10.1210/jc.2014-2496
pubmed: 25514099
Kim, K. et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl Acad. Sci. USA 111, 11774–11779 (2014).
doi: 10.1073/pnas.1410626111
pubmed: 25071169
pmcid: 4136565
Cancer Genome Atlas Research, N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).
doi: 10.1038/nature13385
Der, S. D. et al. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. J. Thorac. Oncol. 9, 59–64 (2014).
doi: 10.1097/JTO.0000000000000042
pubmed: 24305008
Loeser, R. F., Im, H. J., Richardson, B., Lu, Q. & Chubinskaya, S. Methylation of the OP-1 promoter: potential role in the age-related decline in OP-1 expression in cartilage. Osteoarthr. Cartil. 17, 513–517 (2009).
doi: 10.1016/j.joca.2008.08.003
Kron, K. et al. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PloS ONE 4, e4830 (2009).
pubmed: 19283074
pmcid: 2653233
doi: 10.1371/journal.pone.0004830
Dunn, J. & Rao, S. Epigenetics and immunotherapy: the current state of play. Mol. Immunol. 87, 227–239 (2017).
doi: 10.1016/j.molimm.2017.04.012
pubmed: 28511092
Lee, K. S., Hong, S. H. & Bae, S. C. Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein. Oncogene 21, 7156–7163 (2002).
pubmed: 12370805
doi: 10.1038/sj.onc.1205937
Iwasaki, S. et al. Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2. J. Biol. Chem. 274, 26503–26510 (1999).
pubmed: 10473611
doi: 10.1074/jbc.274.37.26503
Awazu, M., Nagata, M. & Hida, M. BMP7 dose-dependently stimulates proliferation and cadherin-11 expression via ERK and p38 in a murine metanephric mesenchymal cell line. Physiol. Rep. 5, e13378 (2017).
Wang, Y. et al. Bone morphogenetic protein-7 prevented epithelial-mesenchymal transition in RLE-6TN cells. Toxicol. Res. 5, 931–937 (2016).
doi: 10.1039/C5TX00471C
Wagner, E. F. & Nebreda, A. R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 9, 537–549 (2009).
pubmed: 19629069
doi: 10.1038/nrc2694
Lee, J. C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739–746 (1994).
pubmed: 7997261
doi: 10.1038/372739a0
Kim, S. H., Kim, J. & Sharma, R. P. Inhibition of p38 and ERK MAP kinases blocks endotoxin-induced nitric oxide production and differentially modulates cytokine expression. Pharmacol. Res. 49, 433–439 (2004).
doi: 10.1016/j.phrs.2003.11.004
pubmed: 14998552
Zhu, W. et al. Regulation of TNF expression by multiple mitogen-activated protein kinase pathways. J. Immunol. 164, 6349–6358 (2000).
doi: 10.4049/jimmunol.164.12.6349
pubmed: 10843689
Baldassare, J. J., Bi, Y. & Bellone, C. J. The role of p38 mitogen-activated protein kinase in IL-1 beta transcription. J. Immunol. 162, 5367–5373 (1999).
pubmed: 10228013
Yang, Y. et al. Functional roles of p38 mitogen-activated protein kinase in macrophage-mediated inflammatory responses. Mediators Inflamm. 2014, 352371 (2014).
pubmed: 24771982
pmcid: 3977509
Yang, W. S. et al. Nanostructured, self-assembling peptide K5 blocks TNF-alpha and PGE(2) production by suppression of the AP-1/p38 pathway. Mediators Inflamm. 2012, 489810 (2012).
pubmed: 22315508
pmcid: 3270444
Byeon, S. E. et al. p38-targeted inhibition of interleukin-12 expression by ethanol extract from Cordyceps bassiana in lipopolysaccharide-activated macrophages. Immunopharmacol. Immunotoxicol. 33, 90–96 (2011).
doi: 10.3109/08923973.2010.482137
pubmed: 20476843
Garcia, J., Lemercier, B., Roman-Roman, S. & Rawadi, G. A Mycoplasma fermentans-derived synthetic lipopeptide induces AP-1 and NF-kappaB activity and cytokine secretion in macrophages via the activation of mitogen-activated protein kinase pathways. J. Biol. Chem. 273, 34391–34398 (1998).
doi: 10.1074/jbc.273.51.34391
pubmed: 9852105
Valledor, A. F. et al. Selective roles of MAPKs during the macrophage response to IFN-gamma. J. Immunol. 180, 4523–4529 (2008).
doi: 10.4049/jimmunol.180.7.4523
pubmed: 18354174
Amirouche, A. et al. Activation of p38 signaling increases utrophin A expression in skeletal muscle via the RNA-binding protein KSRP and inhibition of AU-rich element-mediated mRNA decay: implications for novel DMD therapeutics. Hum. Mol. Genet. 22, 3093–3111 (2013).
doi: 10.1093/hmg/ddt165
pubmed: 23575223
Rincon, M. et al. Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J. 17, 2817–2829 (1998).
pubmed: 9582275
pmcid: 1170622
doi: 10.1093/emboj/17.10.2817
Mavropoulos, A., Sully, G., Cope, A. P. & Clark, A. R. Stabilization of IFN-gamma mRNA by MAPK p38 in IL-12- and IL-18-stimulated human NK cells. Blood 105, 282–288 (2005).
doi: 10.1182/blood-2004-07-2782
pubmed: 15345584
Shoulders, H., Garner, K. H. & Singla, D. K. Macrophage depletion by clodronate attenuates bone morphogenetic protein-7 induced M2 macrophage differentiation and improved systolic blood velocity in atherosclerosis. Transl. Res. 203, 114 (2018).
Gould, S. E., Day, M., Jones, S. S. & Dorai, H. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int 61, 51–60 (2002).
doi: 10.1046/j.1523-1755.2002.00103.x
pubmed: 11786084
Gavenis, K., Pufe, T., Brandenburg, L. O., Schiffl, K. & Schmidt-Rohlfing, B. Effects of controlled released BMP-7 on markers of inflammation and degradation during the cultivation of human osteoarthritic chondrocytes. J. Biomater. Appl. 26, 419–433 (2011).
doi: 10.1177/0885328210374671
pubmed: 20624843
Yang, Y. et al. LPS converts Gr-1(+)CD115(+) myeloid-derived suppressor cells from M2 to M1 via P38 MAPK. Exp. Cell Res. 319, 1774–1783 (2013).
doi: 10.1016/j.yexcr.2013.05.007
pubmed: 23701951
DeSilva, D. R., Jones, E. A., Feeser, W. S., Manos, E. J. & Scherle, P. A. The p38 mitogen-activated protein kinase pathway in activated and anergic Th1 cells. Cell Immunol. 180, 116–123 (1997).
doi: 10.1006/cimm.1997.1182
pubmed: 9341741
Yang, J., Zhu, H., Murphy, T. L., Ouyang, W. & Murphy, K. M. IL-18-stimulated GADD45 beta required in cytokine-induced, but not TCR-induced, IFN-gamma production. Nat. Immunol. 2, 157–164 (2001).
doi: 10.1038/84264
pubmed: 11175814
Yu, J. J., Tripp, C. S. & Russell, J. H. Regulation and phenotype of an innate Th1 cell: role of cytokines and the p38 kinase pathway. J. Immunol. 171, 6112–6118 (2003).
doi: 10.4049/jimmunol.171.11.6112
pubmed: 14634126
Zhang, J. et al. p38 mitogen-activated protein kinase mediates signal integration of TCR/CD28 costimulation in primary murine T cells. J. Immunol. 162, 3819–3829 (1999).
pubmed: 10201899
Matsuda, S., Moriguchi, T., Koyasu, S. & Nishida, E. T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A. J. Biol. Chem. 273, 12378–12382 (1998).
doi: 10.1074/jbc.273.20.12378
pubmed: 9575191
Crawley, J. B. et al. T cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation. J. Biol. Chem. 272, 15023–15027 (1997).
doi: 10.1074/jbc.272.23.15023
pubmed: 9169478
Malhotra, N. & Kang, J. SMAD regulatory networks construct a balanced immune system. Immunology 139, 1–10 (2013).
pubmed: 23347175
pmcid: 3634534
doi: 10.1111/imm.12076
Takimoto, T. et al. Smad2 and Smad3 are redundantly essential for the TGF-beta-mediated regulation of regulatory T plasticity and Th1 development. J. Immunol. 185, 842–855 (2010).
doi: 10.4049/jimmunol.0904100
pubmed: 20548029
Kogkopoulou, O. et al. Conditional up-regulation of IL-2 production by p38 MAPK inactivation is mediated by increased Erk1/2 activity. J. Leukoc. Biol. 79, 1052–1060 (2006).
doi: 10.1189/jlb.0705418
pubmed: 16478922
Veiopoulou, C. et al. IL-2 and IL-10 production by human CD4+T cells is differentially regulated by p38: mode of stimulation-dependent regulation of IL-2. Neuroimmunomodulation 11, 199–208 (2004).
doi: 10.1159/000078437
pubmed: 15249725
Nguyen, T., Wang, R. & Russell, J. H. IL-12 enhances IL-2 function by inducing CD25 expression through a p38 mitogen-activated protein kinase pathway. Eur. J. Immunol. 30, 1445–1452 (2000).
doi: 10.1002/(SICI)1521-4141(200005)30:5<1445::AID-IMMU1445>3.0.CO;2-M
pubmed: 10820392
Martinez, V. G. et al. The BMP Pathway Participates in Human Naive CD4+ T Cell Activation and Homeostasis. PloS ONE 10, e0131453 (2015).
pubmed: 26110906
pmcid: 4481406
doi: 10.1371/journal.pone.0131453
Kroeger, H. et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 112, 1366–1373 (2008).
pubmed: 18523155
pmcid: 2515110
doi: 10.1182/blood-2007-11-126227
Li, J. et al. TCPA: a resource for cancer functional proteomics data. Nat. Methods 10, 1046–1047 (2013).
pubmed: 24037243
pmcid: 4076789
doi: 10.1038/nmeth.2650